for people ages 18 years and up (full criteria)
at Sacramento, California
study started
completion around
Principal Investigator
by Guobao Wang



The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be using other test measures including personal demographics, laboratory blood test results, and imaging measurements to determine the severity of NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), inflammation, and fibrosis.

Official Title

Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study


The study group proposes to evaluate the role of fluorodeoxyglucose (FDG) positron emission tomography (PET) in the determination of steatohepatitis and in combination with MRI for detection, differentiation and quantitation of liver steatosis, steatohepatitis and fibrosis in correlation to liver biopsy. Patient enrolled in this will already have had their liver biopsy or will be undergoing liver biopsy as a part of their clinical care as determined by their provider and will not be getting biopsies solely to be enrolled in the study. Current treatment options for patients that liver biopsy is being performed are limited to lifestyle changes and vitamin E for patients without diabetes.


Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH), Liver Diseases, Fatty Liver, Non-alcoholic Fatty Liver Disease, Fluorodeoxyglucose F18, Fluorodeoxyglucose (FDG) positron emission tomography (PET), Magnetic resonance imaging (MRI), PET Explorer


You can join if…

Open to people ages 18 years and up

  1. Patients >18 years age
  2. Patients who had or will have a liver biopsy as standard of care for fatty liver disease and have risk factors for NASH. Liver biopsy needs to be within 6 months of planned imaging.
  3. Patients undergoing bariatric surgery and will have a liver biopsy as standard of care.
  4. Ability to provide informed consent.

You CAN'T join if...

  1. History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease other than non-alcoholic fatty liver disease.
  2. Pregnant women
  3. Prisoners
  4. Claustrophobic to MRI
  5. Allergic to FDG dye
  6. Patients who are unable to lie in the scanner for one hour


  • University of California Davis Medical Center
    Sacramento California 95817 United States

Lead Scientist at UC Davis

  • Guobao Wang
    Associate Professor, Radiology, School of Medicine. Authored (or co-authored) 50 research publications


accepting new patients
Start Date
Completion Date
University of California, Davis
Learn more or sign up for the study here! Sign up for this study
Study Type
Expecting 120 study participants
Last Updated